EUROPROTEOME announces collaboration with Altana Pharma in molecular profiling of clinical cancer repositories
Advertisement
EUROPROTEOME AG announced that it has entered into a collaboration for evaluation of approaches for molecular profiling of tissue specimens from cancer patients with ALTANA Pharma AG.
Under the agreement, EUROPROTEOME will use its proprietary collection of purified human cancer cells to analyze molecular expression of a panel of cancer targets. The molecular data will then be aligned with a selected set of clinical data such as cancer stage and disease progression in order to assess disease associated expression signatures and prioritize molecular target candidates for therapeutic intervention with novel drugs and accompanying diagnostics for disease control. Financial terms were not disclosed.
"We believe this collaboration will greatly enhance our knowledge about the clinical relevance of novel cancer targets," said Dr. Karl Sanders, Head Therapeutic Area Oncology at ALTANA Pharma AG. "Molecular profiling of tissue specimens from cancer patients will be an important step in the development of novel cancer drugs. This will allow for the stratification of patients who will benefit most from targeted cancer therapeutics. EUROPROTEOME is an ideal partner to achieve this objective."
Christian Knobloch, M.D., Vice President Business Development, EUROPROTEOME, added: "We are very pleased that the value of EEUROPROTEOME's capabilities to merge both molecular and clinical data is being recognized by a top tier pharmaceutical company. We look forward to a successful collaboration."